Manufacturers, Pharmaceutical Industry, GlaxoSmithKline

Big Pharma Should Take Reporting Adverse Events to FDA More Seriously

Searcy Denney Scarola Barnhart & Shipley on 4/19/2016

The U.S. Food and Drug Administration’s requirement that pharmaceutical companies report dangerous side effects cause by medicines they manufacture is being flouted by a few bad actors. Such violations of the federal law are...more

Red Notice Newsletter - August 2015

Akin Gump Strauss Hauer & Feld LLP on 9/1/2015

Welcome to the August 2015 edition of Red Notice, a publication of Akin Gump Strauss Hauer & Feld LLP. This month on the anticorruption front, the U.S. Department of Justice (DOJ) and the U.S. Securities and Exchange...more

The FCPA Year in Review: Twist and Shout (Part I of II)

The Volkov Law Group on 1/6/2015

We all like annual reviews and predictions for the upcoming year – it is a New Year’s rite of passage and one that brings perspective and a sense of order to our otherwise chaotic lives....more

Red Notice Newsleter

Akin Gump Strauss Hauer & Feld LLP on 6/3/2014

Welcome to the May 2014 edition of Red Notice, a publication of Akin Gump Strauss Hauer & Feld LLP. This month, on the anticorruption front, Avon Products, Inc. (“Avon”) agrees to pay USD $135 million to settle a...more

Ten Required Steps To Ensure Effective Compliance Programs By Pharmaceutical And Medical Device Companies (Part III Of III)

The Volkov Law Group on 7/24/2013

In response to the Glaxo controversy and the continuing risks of aggressive FCPA enforcement, drug and device companies need to review and enhance their anti-corruption compliance programs. ...more

Pharmaceutical And Medical Device Companies: Taking It On The Chin (Part II Of III)

The Volkov Law Group on 7/23/2013

As the Glaxo controversy unravels each day, it is important to remember the enforcement context in which the current prosecution in China is occurring. ...more